• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by PetIQ Inc. (Amendment)

    2/13/24 3:54:56 PM ET
    $PETQ
    Other Pharmaceuticals
    Health Care
    Get the next $PETQ alert in real time by email
    SC 13G/A 1 schedule13g.htm SCHEDULE 13G/A Enter title of document
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    SCHEDULE 13G
    
    Under the Securities Exchange Act of 1934
    
    (Amendment No. 2)*
    PetIQ, Inc
    (Name of Issuer)
    Class A Common Stock, $0.001 par value
    (Title of Class of Securities)
    71639T106
    (CUSIP Number)
    December 31, 2023
    (Date of Event which Requires Filing of this Statement)
    
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    
    	[_]  Rule 13d-1(b)
    
    	[x]  Rule 13d-1(c)
    
    	[_]  Rule 13d-1(d)
    
    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
    
    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
    
    
    SCHEDULE 13G
    CUSIP No.	71639T106
    
    1	Names of Reporting Persons
    	Applied Fundamental Research, LLC
    2	Check the appropriate box if a member of a Group (see instructions)
    	(a)  [ ]
    (b)  [ ]
    3	Sec Use Only
    
    4	Citizenship or Place of Organization
    	State of Delaware
    Number of Shares Beneficially Owned by Each Reporting Person With:
    	5	Sole Voting Power
    		0
    	6	Shared Voting Power
    		654,226
    	7	Sole Dispositive Power
    		0
    	8	Shared Dispositive Power
    		654,226
    9	Aggregate Amount Beneficially Owned by Each Reporting Person
    	654,226
    10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
    	[ ]
    11	Percent of class represented by amount in row (9)
    	2.2% (1)
    12	Type of Reporting Person (See Instructions)
    	IA
    (1) The percent of class was calculated based on 29,187,756 shares of Class A common stock issued and outstanding as of November 7, 2023, as disclosed in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 7, 2023.
    
    SCHEDULE 13G
    CUSIP No.	71639T106
    
    1	Names of Reporting Persons
    	AFR CV GP, LLC
    2	Check the appropriate box if a member of a Group (see instructions)
    	(a)  [ ]
    (b)  [ ]
    3	Sec Use Only
    
    4	Citizenship or Place of Organization
    	State of Delaware
    Number of Shares Beneficially Owned by Each Reporting Person With:
    	5	Sole Voting Power
    		0
    	6	Shared Voting Power
    		394,272
    	7	Sole Dispositive Power
    		0
    	8	Shared Dispositive Power
    		394,272
    9	Aggregate Amount Beneficially Owned by Each Reporting Person
    	394,272
    10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
    	[ ]
    11	Percent of class represented by amount in row (9)
    	1.4% (1)
    12	Type of Reporting Person (See Instructions)
    	HC
    (1) The percent of class was calculated based on 29,187,756 shares of Class A common stock issued and outstanding as of November 7, 2023, as disclosed in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 7, 2023.
    
    SCHEDULE 13G
    CUSIP No.	71639T106
    
    1	Names of Reporting Persons
    	AFR VP GP, LLC
    2	Check the appropriate box if a member of a Group (see instructions)
    	(a)  [ ]
    (b)  [ ]
    3	Sec Use Only
    
    4	Citizenship or Place of Organization
    	State of Delaware
    Number of Shares Beneficially Owned by Each Reporting Person With:
    	5	Sole Voting Power
    		0
    	6	Shared Voting Power
    		34,632
    	7	Sole Dispositive Power
    		0
    	8	Shared Dispositive Power
    		34,632
    9	Aggregate Amount Beneficially Owned by Each Reporting Person
    	34,632
    10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
    	[ ]
    11	Percent of class represented by amount in row (9)
    	0.1% (1)
    12	Type of Reporting Person (See Instructions)
    	HC
    (1) The percent of class was calculated based on 29,187,756 shares of Class A common stock issued and outstanding as of November 7, 2023, as disclosed in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 7, 2023.
    
    SCHEDULE 13G
    CUSIP No.	71639T106
    
    1	Names of Reporting Persons
    	AFR Concentrated Value, LP
    2	Check the appropriate box if a member of a Group (see instructions)
    	(a)  [ ]
    (b)  [ ]
    3	Sec Use Only
    
    4	Citizenship or Place of Organization
    	State of Delaware
    Number of Shares Beneficially Owned by Each Reporting Person With:
    	5	Sole Voting Power
    		0
    	6	Shared Voting Power
    		394,272
    	7	Sole Dispositive Power
    		0
    	8	Shared Dispositive Power
    		394,272
    9	Aggregate Amount Beneficially Owned by Each Reporting Person
    	394,272
    10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
    	[ ]
    11	Percent of class represented by amount in row (9)
    	1.4% (1)
    12	Type of Reporting Person (See Instructions)
    	PN
    (1) The percent of class was calculated based on 29,187,756 shares of Class A common stock issued and outstanding as of November 7, 2023, as disclosed in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 7, 2023.
    
    SCHEDULE 13G
    CUSIP No.	71639T106
    
    1	Names of Reporting Persons
    	AFR Value Partners, LP
    2	Check the appropriate box if a member of a Group (see instructions)
    	(a)  [ ]
    (b)  [ ]
    3	Sec Use Only
    
    4	Citizenship or Place of Organization
    	State of Delaware
    Number of Shares Beneficially Owned by Each Reporting Person With:
    	5	Sole Voting Power
    		0
    	6	Shared Voting Power
    		34,632
    	7	Sole Dispositive Power
    		0
    	8	Shared Dispositive Power
    		34,632
    9	Aggregate Amount Beneficially Owned by Each Reporting Person
    	34,632
    10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
    	[ ]
    11	Percent of class represented by amount in row (9)
    	0.1% (1)
    12	Type of Reporting Person (See Instructions)
    	PN
    (1)	The percent of class was calculated based on 29,187,756 shares of Class A common stock issued and outstanding as of November 7, 2023, as disclosed in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 7, 2023.
    
    SCHEDULE 13G
    CUSIP No.	71639T106
    (2)
    1	Names of Reporting Persons
    	Theodore Wagenknecht
    2	Check the appropriate box if a member of a Group (see instructions)
    	(a)  [ ]
    (b)  [ ]
    3	Sec Use Only
    
    4	Citizenship or Place of Organization
    	United States
    Number of Shares Beneficially Owned by Each Reporting Person With:
    	5	Sole Voting Power
    		0
    	6	Shared Voting Power
    		654,226
    	7	Sole Dispositive Power
    		0
    	8	Shared Dispositive Power
    		654,226
    9	Aggregate Amount Beneficially Owned by Each Reporting Person
    	654,226
    10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
    	[ ]
    11	Percent of class represented by amount in row (9)
    	2.2% (1)
    12	Type of Reporting Person (See Instructions)
    	IN, HC
    (1)	The percent of class was calculated based on 29,187,756 shares of Class A common stock issued and outstanding as of November 7, 2023, as disclosed in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 7, 2023.
    Item 1.
    (a)	Name of Issuer:
    PetIQ, Inc.
    (b)	Address of Issuer's Principal Executive Offices:
    230 E. Riverside Dr.
    Eagle, ID 83616
    Item 2.
    (a)	Name of Person Filing:
    (i)	Applied Fundamental Research, LLC ("AFR" or the "Investment Manager") as the investment manager to private investment funds and third-party managed accounts;
    (ii)	AFR Concentrated Value, LP ("AFR CV"), a Delaware limited partnership, as a private fund;
    (iii)	 AFR Value Partners, LP ("AFR VP", and collectively with AFR CV, the "Funds"), a Delaware limited partnership, as a private fund;
    (iv)	 AFR CV GP, LLC ("AFR CV GP"), a Delaware limited liability company, as the General Partner of AFR CV;
    (v)	AFR VP GP, LLC ("AFR VP GP"), a Delaware limited liability company, as the General Partner of AFR VP;
    (vi)	Theodore Wagenknecht, a United States citizen.
    The foregoing persons are sometimes individually referred to herein as a "Reporting Person" and collectively as the "Reporting Persons". AFR is also the investment manager for certain third-party accounts (the "Managed Accounts") for whose benefit shares of the Company are held and managed by AFR.
    (b)	Address of Principal Business Office or, if None, Residence:
    50 Church Street, 5th Floor, Cambridge, MA 02138
    (c)	Citizenship:
    Each of the Investment Manager and the Funds' General Partners is a Delaware limited liability company. Each of the Funds is a Delaware limited partnership. Mr. Wagenknecht is a United States citizen.
    (d)	Title and Class of Securities:
    Class A Common Stock, $0.001 par value
    (e)	CUSIP No.:
    71639T106
    Item 3. 	If this statement is filed pursuant to Par. 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)	[_]	Broker or dealer registered under Section 15 of the Act;
    (b)	[_]	Bank as defined in Section 3(a)(6) of the Act;
    (c)	[_]	Insurance company as defined in Section 3(a)(19) of the Act;
    (d)	[_]	Investment company registered under Section 8 of the Investment Company Act of 1940;
    (e)	[_]	An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
    (f)	[_]	An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
    (g)	[_]	A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
    (h)	[_]	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)	[_]	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940;
    (j)	[_]	A non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J);
    (k)	[_]	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____
    Item 4.	Ownership
    For each Reporting Person:
    (a)	Amount Beneficially Owned:  	 See Item 9 of each cover page
     (b)	Percent of Class:  See Item 11 of each cover page*
     (c)	Number of shares as to which such person has:
    	(i)	Sole power to vote or to direct the vote: See Item 5 of each cover page
    	(ii)	Shared power to vote or to direct the vote: See Item 6 of each cover page
    (iii)	Sole power to dispose or to direct the disposition of: See Item 7 of each cover page
    (iv)	Shared power to dispose or to direct the disposition of: See Item 8 of each cover page
    Shares reported herein for the Investment Manager and the Funds' General Partners represent Class A Common Stock beneficially owned and held of record by the Funds for which the Investment Manager serves as the investment manager and the Funds' General Partners serve as general partners. Shares reported herein for Mr. Wagenknecht represent Class A Common Stock beneficially owned and held of record by the Funds and the Managed Accounts. Mr. Wagenknecht is the managing member of the Investment Manager and the Funds' General Partners.
    AFR is also the investment manager for certain Managed Accounts for which shares of the Company are held and managed by AFR for the benefit of such third parties. AFR has dispositive power and shares certain voting power with respect to such shares. As of the date of this filing, there are 225,322 shares of Class A Common Stock of the Company held in such Managed Accounts, and the securities reported on the attached cover page(s) include such shares.
    * The percent of class was calculated based on 29,187,756 shares of Class A common stock issued and outstanding as of November 7, 2023, as disclosed in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 7, 2023.
    Item 5.	Ownership of Five Percent or Less of a Class.
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [  x  ].
    Item 6.	Ownership of more than Five Percent on Behalf of Another Person.
    Not Applicable
    Item 7.	Identification and classification of the subsidiary which acquired the security being reported on by the parent holding company or control person.
    The sole general partner of AFR CV is AFR CV GP. The sole general partner of AFR VP is AFR VP GP. AFR is the Investment Manager of AFR CV and AFR VP.  Each of AFR CV GP, AFR VP GP and AFR may be deemed to be the beneficial owner of all shares held directly by AFR CV, AFR VP and the Managed Accounts.
    Item 8.	Identification and classification of members of the group.
    Not Applicable
    Item 9.	Notice of Dissolution of Group.
    Not Applicable
    Item 10.	Certifications.
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
    
    
    SIGNATURE
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
    Dated:  February 13, 2024
    
    AFR Concentrated Value, L.P.
    By: AFR CV GP, LLC
    its general partner
    By: /s/ Theodore Wagenknecht
    Managing Member
    
    AFR Value Partners, L.P.
    By: AFR VP GP, LLC
    its general partner
    By: /s/ Theodore Wagenknecht
    Managing Member
    
    AFR CV GP, LLC
    By: /s/ Theodore Wagenknecht
    Managing Member
    
    AFR VP GP, LLC
    By: /s/ Theodore Wagenknecht
    Managing Member
    
    Applied Fundamental Research, LLC
    By: /s/ Denitsa Brown
    Denitsa Brown, Chief Compliance Officer and Director of Finance
    
    
    Get the next $PETQ alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PETQ

    DatePrice TargetRatingAnalyst
    8/8/2024$30.00 → $31.00Buy → Hold
    Truist
    12/19/2023$22.00Buy
    Jefferies
    9/6/2023$28.00Buy
    Lake Street
    5/13/2022Outperform → Perform
    Oppenheimer
    3/3/2022$32.00 → $29.00Outperform
    Raymond James
    11/30/2021$30.00Buy
    The Benchmark Company
    11/30/2021$30.00Buy
    Benchmark
    11/4/2021$41.00 → $32.00Outperform
    Raymond James
    More analyst ratings

    $PETQ
    SEC Filings

    View All

    SEC Form 15-12G filed by PetIQ Inc.

    15-12G - PetIQ, Inc. (0001668673) (Filer)

    11/4/24 4:27:39 PM ET
    $PETQ
    Other Pharmaceuticals
    Health Care

    SEC Form S-8 POS filed by PetIQ Inc.

    S-8 POS - PetIQ, Inc. (0001668673) (Filer)

    10/25/24 9:19:31 AM ET
    $PETQ
    Other Pharmaceuticals
    Health Care

    SEC Form S-8 POS filed by PetIQ Inc.

    S-8 POS - PetIQ, Inc. (0001668673) (Filer)

    10/25/24 9:10:10 AM ET
    $PETQ
    Other Pharmaceuticals
    Health Care

    $PETQ
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    PetIQ downgraded by Truist with a new price target

    Truist downgraded PetIQ from Buy to Hold and set a new price target of $31.00 from $30.00 previously

    8/8/24 6:48:12 AM ET
    $PETQ
    Other Pharmaceuticals
    Health Care

    Jefferies initiated coverage on PetIQ with a new price target

    Jefferies initiated coverage of PetIQ with a rating of Buy and set a new price target of $22.00

    12/19/23 6:55:11 AM ET
    $PETQ
    Other Pharmaceuticals
    Health Care

    Lake Street initiated coverage on PetIQ with a new price target

    Lake Street initiated coverage of PetIQ with a rating of Buy and set a new price target of $28.00

    9/6/23 9:07:45 AM ET
    $PETQ
    Other Pharmaceuticals
    Health Care

    $PETQ
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Glasman Zvi returned 25,800 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - PetIQ, Inc. (0001668673) (Issuer)

    10/28/24 3:10:31 PM ET
    $PETQ
    Other Pharmaceuticals
    Health Care

    Director Huff Scott returned 6,077 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - PetIQ, Inc. (0001668673) (Issuer)

    10/28/24 3:10:13 PM ET
    $PETQ
    Other Pharmaceuticals
    Health Care

    EVP Manufacturing & Sup. Chain Lyon Chad D. returned 10,659 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - PetIQ, Inc. (0001668673) (Issuer)

    10/28/24 3:00:00 PM ET
    $PETQ
    Other Pharmaceuticals
    Health Care

    $PETQ
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    PetIQ Names Camillo Pane as Chief Executive Officer

    Accomplished Consumer Goods and Health Care LeaderWould Bring Decades of Leadership Experience to Role EAGLE, Idaho, Feb. 11, 2025 (GLOBE NEWSWIRE) -- PetIQ, Inc. ("PetIQ" or the "Company"), a leading pet medication, health and wellness company and portfolio company of Bansk Group, is pleased to announce that Camillo Pane would join PetIQ as Chief Executive Officer, effective February 17, 2025. Mr. Pane would succeed Cord Christensen. Mr. Pane's passion for making a difference in the lives of consumers has been a constant focus throughout his more than 30-year career. His drive and commitment in this area has led to strong share gains and profitable growth at a variety of iconic consumer

    2/11/25 10:00:00 AM ET
    $PETQ
    Other Pharmaceuticals
    Health Care

    PetIQ, Inc. Announces Successful Completion of Acquisition by Bansk Group

    EAGLE, Idaho and NEW YORK, Oct. 25, 2024 (GLOBE NEWSWIRE) -- PetIQ, Inc. ("PetIQ" or the "Company") (NASDAQ:PETQ), a leading pet medication, health and wellness company, today announced the successful completion of its acquisition by Bansk Group ("Bansk"), a consumer-focused private investment firm dedicated to building distinctive consumer brands, in an all-cash transaction valued at approximately $1.5 billion. PetIQ stockholders will receive $31.00 in cash per PetIQ share in accordance with the terms of the transaction. With the completion of the transaction, PetIQ shares no longer trade on and will be delisted from the Nasdaq stock exchange. PetIQ is now a privately held company and co

    10/25/24 8:45:00 AM ET
    $PETQ
    Other Pharmaceuticals
    Health Care

    PetIQ, Inc. Announces Results of Special Meeting of Stockholders

    EAGLE, Idaho, Oct. 22, 2024 (GLOBE NEWSWIRE) -- PetIQ, Inc. ("PetIQ" or the "Company") (NASDAQ:PETQ), a leading pet medication, health and wellness company, announced today that at its virtual Special Meeting of Stockholders approximately 80% of its outstanding shares of common stock voted to approve the adoption of the definitive merger agreement (the "Agreement") pursuant to which Bansk Group will acquire all of the outstanding shares of PetIQ's common stock for $31.00 per share, in an all-cash transaction valued at approximately $1.5 billion. "On behalf of PetIQ's Board of Directors, we are excited to announce stockholders' approval of our proposed transaction with Bansk Group, repre

    10/22/24 4:05:00 PM ET
    $PETQ
    Other Pharmaceuticals
    Health Care

    $PETQ
    Leadership Updates

    Live Leadership Updates

    View All

    PetIQ Names Camillo Pane as Chief Executive Officer

    Accomplished Consumer Goods and Health Care LeaderWould Bring Decades of Leadership Experience to Role EAGLE, Idaho, Feb. 11, 2025 (GLOBE NEWSWIRE) -- PetIQ, Inc. ("PetIQ" or the "Company"), a leading pet medication, health and wellness company and portfolio company of Bansk Group, is pleased to announce that Camillo Pane would join PetIQ as Chief Executive Officer, effective February 17, 2025. Mr. Pane would succeed Cord Christensen. Mr. Pane's passion for making a difference in the lives of consumers has been a constant focus throughout his more than 30-year career. His drive and commitment in this area has led to strong share gains and profitable growth at a variety of iconic consumer

    2/11/25 10:00:00 AM ET
    $PETQ
    Other Pharmaceuticals
    Health Care

    PetIQ, Inc. Appoints John Pearson to Executive Vice President, Services & Manufactured Products

    EAGLE, Idaho, Aug. 02, 2023 (GLOBE NEWSWIRE) -- PetIQ, Inc. ("PetIQ" or the "Company") (NASDAQ:PETQ), a leading pet medication and wellness company, today announced that John Pearson, who has served as the Company's Senior Vice President, Head of Services since 2022, has been appointed Executive Vice President, Services & Manufactured Products, a newly created role, effective August 2, 2023. In his new role, Pearson will gain responsibility for PetIQ's manufactured product portfolio, inclusive of the Company's sales and marketing teams, while maintaining his current responsibilities for the Services segment. Pearson will continue to report directly to Michael Smith, President and Chief Ope

    8/2/23 8:00:00 AM ET
    $PETQ
    Other Pharmaceuticals
    Health Care

    Simple Mills Appoints Sheryl O'Loughlin to Board of Directors

    #1 Cookie, Cracker, and Baking Mix Brand in the Natural Channel Taps Industry Veteran to Provide Guidance in Innovation and Sustainability Simple Mills, the company on a mission to advance the holistic health of the planet and its people through delicious, better-for-you foods, today announced the addition of CPG industry veteran, Sheryl O'Loughlin, to its Board of Directors. O'Loughlin is an accomplished entrepreneur, CEO, author, and board member bringing extensive experience leading fast-growing, innovative consumer products companies. In her new role, O'Loughlin will provide strategic counsel and guidance to help support Simple Mills in scaling the company to the next level, creating o

    11/29/22 8:03:00 AM ET
    $PETQ
    Other Pharmaceuticals
    Health Care

    $PETQ
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by PetIQ Inc.

    SC 13G/A - PetIQ, Inc. (0001668673) (Subject)

    11/14/24 6:36:50 PM ET
    $PETQ
    Other Pharmaceuticals
    Health Care

    Amendment: SEC Form SC 13G/A filed by PetIQ Inc.

    SC 13G/A - PetIQ, Inc. (0001668673) (Subject)

    11/12/24 5:02:29 PM ET
    $PETQ
    Other Pharmaceuticals
    Health Care

    Amendment: SEC Form SC 13G/A filed by PetIQ Inc.

    SC 13G/A - PetIQ, Inc. (0001668673) (Subject)

    11/4/24 11:49:14 AM ET
    $PETQ
    Other Pharmaceuticals
    Health Care

    $PETQ
    Financials

    Live finance-specific insights

    View All

    PetIQ, Inc. Reports Second Quarter 2024 Financial Results

    Generates Record Second Quarter 2024 Net Sales and Net IncomeRecord Adjusted EBITDA of $39.0 Million Exceeds Company's Second Quarter 2024 GuidancePetIQ and Bansk Group Sign Definitive Merger Agreement EAGLE, Idaho, Aug. 07, 2024 (GLOBE NEWSWIRE) -- PetIQ, Inc. ("PetIQ" or the "Company") (NASDAQ:PETQ), a leading pet medication, product and wellness company, today reported financial results for the second quarter and six months ended June 30, 2024. Cord Christensen, PetIQ's Founder and CEO, commented, "We are very pleased to report another quarter of record financial results. The strength of PetIQ's brands fueled second quarter profitability that exceeded our expectati

    8/7/24 8:01:00 AM ET
    $PETQ
    Other Pharmaceuticals
    Health Care

    PetIQ, Inc. to Report Second Quarter 2024 Financial Results on Wednesday, August 7, 2024

    EAGLE, Idaho, July 17, 2024 (GLOBE NEWSWIRE) -- PetIQ, Inc. ("PetIQ" or the "Company") (NASDAQ:PETQ), a leading pet medication, health and wellness company, today announced it will report financial results for the second quarter and six months ended June 30, 2024, on Wednesday, August 7, 2024, after the market close. The Company will host a conference call with members of the executive management team to discuss these results. The conference call is scheduled to begin at 4:30 p.m. ET on Wednesday, August 7, 2024. To listen to the live call participants in North America may dial 833-816-1410 and international participants may dial 412-317-0503. In addition, the call will be broadcast live

    7/17/24 4:05:00 PM ET
    $PETQ
    Other Pharmaceuticals
    Health Care

    PetIQ, Inc. Reports First Quarter 2024 Financial Results

    Reports Record First Quarter 2024 Net Sales of $308.4 MillionAchieves Record First Quarter Net IncomeRecord Adjusted EBITDA Exceeds Company's First Quarter 2024 GuidanceRaises Full Year 2024 Outlook EAGLE, Idaho, May 08, 2024 (GLOBE NEWSWIRE) -- PetIQ, Inc. ("PetIQ" or the "Company") (NASDAQ:PETQ), a leading pet medication, product and wellness company, today reported financial results for the first quarter ended March 31, 2024. Cord Christensen, PetIQ's Founder and CEO commented, "We've started 2024 off well with broad-based growth and strong pet parent demand for our product offerings. PetIQ's manufactured brands captured a disproportionate amount of their category market share to fuel

    5/8/24 4:05:00 PM ET
    $PETQ
    Other Pharmaceuticals
    Health Care